Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Intelligent Image Analysis Speeds Up Drug Discovery

By Catherine Sbeglia | July 17, 2018

It seems that every part of the drug development and manufacturing process is moving toward automation, often improving processing speeds and information accuracy. Continuing this trend of increased automation is French company, Biocellvia, which provides intelligent, automated image analysis that identifies and evaluates candidate drug molecules for preclinical disease models.

Pharmaceutical Processing spoke with Olivier Julé, CEO and co-founder of Biocellvia about how this technology drastically speeds up drug discovery and development while ensuring accuracy.

Preclinical trials is where a drug’s efficacy is first determined, making this early stage of the process vital. Traditionally, a candidate molecule is evaluated using the scoring method, which relies on visual assessments made by pathologists. However, scores have been known to vary among pathologists, calling into question the accuracy and reliability of the scoring method. Additionally, according to Julé, the traditional scoring method can take about six weeks to complete.

Julé told Pharmaceutical Processing about the risks associated with visual assessments, explaining that “visual assessment takes time away from pathologists who can be concentrating on higher value tasks. Human intervention also brings subjectivity and variability. This is a well-known challenge in the field. For example, pathologists realize manual annotations on sections, or manual sweeping and each of these can result in errors. We want to reduce human intervention in order to reduce variability.”

Top image: Merge fibrosis identification (in orange density of parenchymal tissue) on a whole lung section. Bottom image: Identification of lipid vacuole on a NASH liver in order to quantify steatosis. (Credit: Biocellvia)

Preclinical trials are time and labor consuming and can provide only limited accuracy, a fact even more problematic when the odds of discovering a drug compound that will make it all the way through to approval are on average one in 5,000.

“Biocellvia’s digital image analysis brings accuracy, reliability, and reproducibility thanks to quantitative and morphometric robust and objective data,” Julé claims. “Our technology is a smart decision-making tool that tells us if we should move forward with the study of the lead molecules from preclinical stage to clinical stage.”

Furthermore, the fully-automated technology can provide this information in 48 hours, compared to the nearly month and half it takes when using the traditional scoring method. The imaging technology can analyze approximately 100 images per hour.

Drug discovery and development are expensive and contribute significantly to the high drugs prices that plague U.S. patients across the country. Technologies like the one developed by Biocellvia have the potential to lower back end drug development costs, and possibly pass those cost reductions along to patients.  

In collaboration with Boehringer Ingelheim, Biocellvia created a program dedicated to pulmonary fibrosis, publishing a scientific paper on the findings. Following this development, the company created programs for respiratory diseases and NASH (liver fibrosis). Julé says the company is currently developing image analysis programs dedicated to oncology.

(Sources: The New York Times; POLS One)


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE